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Introduction {#sec006}
============

Mental disorders are one of the largest contributors toward the global burden of disease, being responsible for 21.2% of years lived with disability (YLDs) \[[@pone.0217406.ref001]\] and affecting approximately 1 in 5 adults within a given 12 month period and about 1 in 3 at some point in their lives. \[[@pone.0217406.ref002]\] However, the quality of care provided to patients with mental illness compared to those with physical health illnesses has been found to be inferior, and their care needs may often remain unmet \[[@pone.0217406.ref003]\], including the management of comorbid physical conditions \[[@pone.0217406.ref004]\].

Medications are the most frequently used type of treatment for mental disorders \[[@pone.0217406.ref005]\], yet there are unique challenges when prescribing for this population. These include the enduring problem of high dose and combination antipsychotic prescribing, use of a number of high risk drugs (e.g. lithium, clozapine), the requirements of mental health law, co-existing substance misuse which may cause interactions with prescribed therapy and a high prevalence of poor lifestyle, multiple comorbidities and polypharmacy which can cause drug--disease and drug-drug interactions \[[@pone.0217406.ref006]\]. Taking all these factors into account, it may be difficult to achieve balanced prescribing for patients with mental illness \[[@pone.0217406.ref007]\].

Against this background of underlying complexity there is evidence that prescribing errors and substandard prescribing might be common in this patient group. In 2016, a Danish study found that 59% of patients admitted to a psychiatric hospital had at least one potentially inappropriate prescription (PIP), with 45% of PIPs being potentially serious or fatal \[[@pone.0217406.ref007]\]. In addition, a systematic review of medication errors in mental health hospitals published in 2017 reported that between 52.2--82.1% of patients may be affected by prescribing errors \[[@pone.0217406.ref008]\].

In order to improve the quality and safety of healthcare services provided to those with mental disorders it is important to be able to measure them. Indicators have been used widely to assess the quality of healthcare services, including prescribing. However, many prescribing indicators focus on the effectiveness of prescribing and not safety, which is important to address given the known risks prescribing can pose to patient safety \[[@pone.0217406.ref009]\]. Indicators that measure unsafe prescribing are known as Prescribing safety indicators (PSIs); these are statements describing potentially hazardous prescribing and drug monitoring that may put the patient at increased risk of harm. \[[@pone.0217406.ref010]\] Even though these prescribing patterns are not considered good practice and should generally be avoided, not all of them may necessarily be errors, and they may require judgement from the patient and clinical team. \[[@pone.0217406.ref011]\] The purpose of these types of indicators may therefore act as a prompt for clinical review to determine whether changes are required.

PSIs have been used to estimate the level of variation in prescribing safety between practices \[[@pone.0217406.ref012]\], to observe change after interventions \[[@pone.0217406.ref013]\], and to develop clinical decision support (CDS) alerts in computerized provider order entry (CPOE) \[[@pone.0217406.ref014], [@pone.0217406.ref015]\]. Awareness of the potential value of PSIs has grown, with recent deployment in England of a national medication safety dashboard to monitor a limited set of PSIs to inform safer prescribing \[[@pone.0217406.ref016]\]. Elsewhere, PSIs have driven the development of the successful pharmacist-led information technology intervention for medication errors (PINCER) approach \[[@pone.0217406.ref017]\] which now features in UK National Institute for Health and Care Excellence (NICE) guidance for medicines optimisation \[[@pone.0217406.ref018]\]. However, whilst numerous sets of prescribing quality and safety indicators and inappropriate prescribing criteria have been developed for different populations and settings \[[@pone.0217406.ref019], [@pone.0217406.ref020]\], mental health illnesses and the medications used to treat them have not received as much attention in this regard.

Whilst there are a number of informative academic papers describing the development of broad suites of PSIs across primary \[[@pone.0217406.ref010], [@pone.0217406.ref021]\] and secondary care \[[@pone.0217406.ref015]\] that include some mental health related indicators, these were not developed to be used specifically for populations with mental illness. In addition, existing systematic reviews of broader categories of prescribing indicators \[[@pone.0217406.ref019], [@pone.0217406.ref020]\] have only identified one existing mental health specific set of prescribing quality indicators \[[@pone.0217406.ref022]\]. However, this set may not reflect current practice since it was published 14 years ago, and does not address many known areas of potentially hazardous prescribing in those with mental illness such as medication monitoring issues and omissions \[[@pone.0217406.ref022]\]. Previous systematic reviews were also affected by limitations, such as not including all known types of prescribing assessment tools \[[@pone.0217406.ref019], [@pone.0217406.ref020]\]. It is therefore of importance that existing prescribing indicators and suites of all kinds that are relevant to those with mental illness are identified and those considered to be potential PSIs subsequently extracted, as without a suitable tool in place efforts to improve the safety of health care may be limited in this population.

The aim of this systematic review was therefore to identify comprehensively from the existing literature published prescribing indicators and suites of all kinds from across all settings, and to extract from these any individual potential prescribing safety indicators or whole tools that are related to mental health disorders and medications.

Methods {#sec007}
=======

In order to achieve the aim of this systematic review, we followed three stages ([Fig 1](#pone.0217406.g001){ref-type="fig"}); (1) identifying studies that reported prescribing indicators of any kind; (2) identifying and extracting mental health (MH) related prescribing indicators; and (3) selecting potential PSIs related to MH disorders and medications.

![Systematic review stages.\
MH = Mental health. PSI = Prescribing Safety Indicators.](pone.0217406.g001){#pone.0217406.g001}

Stage 1: Identifying studies that reported prescribing indicators of any kind {#sec008}
-----------------------------------------------------------------------------

### Database search strategy {#sec009}

A systematic search was conducted using the following electronic databases: Embase, MEDLINE, PsycINFO, Web of Science, Health Management Information Consortium (HMIC), International Pharmaceutical Abstracts (IPA) and Cumulative Index to Nursing and Allied Health Literature (CINAHL). The search strategy was designed using Medical Subject Headings (MeSH) and free text words tailored to each database ([S1 File](#pone.0217406.s001){ref-type="supplementary-material"}). Three sets of search terms were combined; medication safety terms, quality measure terms and indicators development/validation terms. The search timeframe was limited from January 1990 to February 2019, since one of the earliest examples of inappropriate prescribing explicit criteria was published in 1991 by Beers \[[@pone.0217406.ref023], [@pone.0217406.ref024]\]. The bibliographies of included studies and of relevant review articles were reviewed manually to identify additional citations.

The search results were assessed for eligibility by screening the title and abstract by one reviewer (WK). Afterwards, the full-texts of potentially relevant articles were each reviewed for inclusion by WK. Any uncertainty regarding the eligibility of an article was discussed by the research team until consensus was reached.

### Definitions {#sec010}

The term 'indicator' was used to describe all the different types of prescribing indicator/criteria. Explicit indicators were included in the study and can be described as drug- or disease-oriented indicators that can be applied as firm standards (e.g. prescribing Benzodiazepines for ≥ 4 weeks for elderly patients \[[@pone.0217406.ref025]\]). Implicit indicators are person-specific, and their use requires professional skills (e.g. is there an indication for the drug? \[[@pone.0217406.ref026]\]) and were not included in this review.

### Inclusion criteria {#sec011}

Articles were eligible for inclusion if they developed, validated or updated a set of explicit indicators or criteria that measured prescribing in terms of safety or quality, including inappropriate prescribing, prescribing errors, hazardous prescribing, prescribing faults, monitoring errors or any other term that might be used to describe prescribing safety or quality. As the initial aim was to capture all relevant materials so that mental health indicators could be identified, there were no restrictions on the type of study design, targeted setting, the age group the indicators were intended for use in, publication language and intended country for deployment. All relevant articles were included whether they featured any mental health related indicators or not.

### Exclusion criteria {#sec012}

We excluded articles that developed implicit indicators only (e.g. is there an indication for the drug? \[[@pone.0217406.ref026]\]), because they were not drug- or disease-oriented. We also excluded articles that developed indicators based on aggregate data and did not have any relation to patient level data (e.g. Ratio of co-trimoxazole items to trimethoprim items \[[@pone.0217406.ref027]\]). Studies that developed indicators non-specific to a medication or therapeutic class were also excluded (e.g. If the duration of a drug is outside the range stated in the British National Formulary (BNF) \[[@pone.0217406.ref028]\]), as were conference abstracts unless we were able to obtain the full indicator list. Studies that measured the prevalence of prescribing quality or safety, using a previously published prescribing indicator suite/tool without further development were considered duplicates and were not included, as were those involving adaptation/translation of single published prescribing indicator suite/tool to be used in another country without further development. Studies describing sets of indicators exclusively limited to a specific disease or specific therapeutic drug class that were not related to mental health medications and/or illnesses were also excluded (e.g. prescribing quality indicators for patients with type 2 diabetes \[[@pone.0217406.ref029]\]), as were those studies whose main focus was not prescribing (e.g. assessing care of vulnerable elders (ACOVE) quality indicators \[[@pone.0217406.ref030]\]).

### Data extraction {#sec013}

The data extraction process for each study was conducted independently by two authors into a standardised and piloted electronic data extraction sheet. Discrepancies were discussed by the research team until agreement was reached. The following data were extracted from each included study where presented: **Study information:** Study title, main author, country, aim of the study. **Study design:** Setting, targeted population, indicators sources, validation methods. **Results**: Total number and type of indicators.

### Quality assessment {#sec014}

Due to the heterogeneity of the included studies objectives and methods, we did not formally assess the methodological quality of the included studies. In addition, even though most studies used a consensus approach to develop their indicators, to our knowledge, there are no formal tools to assess the quality of consensus-based studies. However, certain aspects of the quality of the included studies are discussed later in this paper, such as the methods used to select indicators and the process to validate the indicators.

Stage 2: Identifying and extracting MH related prescribing indicators {#sec015}
---------------------------------------------------------------------

All included studies from the first stage were screened to identify and extract all mental health related indicators based on the definition in [Box 1](#pone.0217406.box001){ref-type="boxed-text"}.

### Box 1. mental health related indicators definition {#sec016}

Indicators were defined as mental health related if they included:

1.  A medication that can be used to treat or prevent any mental health condition (e.g. prescribing atypical antipsychotic for elderly **\[[@pone.0217406.ref031], [@pone.0217406.ref032]\]**), unless the indicator was specific for a non-mental health indication (e.g. clonidine for the treatment of arterial hypertension in the elderly **\[[@pone.0217406.ref033]\]**),

2.  A medication that can be used to treat or prevent side effects of any of the medications that can be used to treat or prevent any mental health condition (e.g. Trihexyphenidyl for treatment of extrapyramidal symptoms caused by antipsychotics for elderly **\[[@pone.0217406.ref034]\]**), unless the indicator were specific for a non-mental related health indication, or

3.  A drug-disease interaction of any medication with any mental health condition (e.g. H2 receptors antagonist **\[[@pone.0217406.ref034]\]** or antimuscarinic drugs **\[[@pone.0217406.ref025]\]** with dementia, or chronic cognitive impairment in elderly).

The following information sources were used to determine the uses of each medication when screening for mental health related indicators: British National Formulary, Martindale, AHFS Drug Information (all accessed via Medicines complete\[[@pone.0217406.ref035]\]). In addition, International Classification of Diseases, 10th revision (ICD-10) Chapter 5: Mental and behavioural disorders \[[@pone.0217406.ref036]\] and Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) \[[@pone.0217406.ref037]\] were used to determine mental health conditions.

Some indicators were considered mental health related because they included medication within a wider therapeutic class that could be used to treat mental health conditions, such as first-generation antihistamines. It was not always clear whether all medication within certain classes may be used to treat mental health disorders, however the class was included due to variation between clinical practice in different countries but only if more than one medication within that class was identified as being used in the treatment of mental illness. Conversely, some other classes were not included entirely as mental health related, because only one of the medications within that class could be used in the treatment of mental illness (e.g. clonidine).

After identifying all mental health related indicators, duplicates were removed, and if an indicator included more than one medication, class or condition it was split into more than one. For example, *"Benzodiazepine or benzodiazepine-like drug prescribed to a patient with chronic obstructive pulmonary disease \[[@pone.0217406.ref015]\]"*, was split into two indicators, one for benzodiazepine and another for benzodiazepine-like drug. In addition, in regards to the identified outcome indicators, these included an adverse outcome that was caused by a pattern of care (for example: Outcome: Fall and/or hip fracture and/or other bone fracture and/or bone break, Process of care: Use of a long-half-life hypnotic-anxiolytic \[[@pone.0217406.ref038]\]). For such indicators, we only extracted the process of care that leads to the outcome in our list of potential indicators.

The identified mental health related indicators were categorised according to the type of prescribing problem (potentially inappropriate medication (PIM): independent of diagnoses or conditions, PIM: considering diagnoses or conditions, drug-drug interaction (DDI), inappropriate dosing, inappropriate duration, inadequate monitoring and omission) ([Table 1](#pone.0217406.t001){ref-type="table"}), these categories were adapted from previous studies. \[[@pone.0217406.ref039]--[@pone.0217406.ref041]\]. Identified indicators were also categorised to their therapeutic class (Antipsychotics, Antidepressants, Sedatives, hypnotics and anxiolytics, attention deficit hyperactivity disorder (ADHD) medications, Anti-dementia, Mood stabilisers, Non-specific anticholinergics and Non-specific psychotropics). The numbers and percentages of the indicators in each category were calculated.

10.1371/journal.pone.0217406.t001

###### Descriptions and examples of the types of prescribing problems.

![](pone.0217406.t001){#pone.0217406.t001g}

  Type of prescribing problem                       Description                                                                                                Example
  ------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **PIM: independent of diagnoses or conditions**   Medication/class that is potentially prescribed inappropriately to a specific population                   Prescribing antipsychotics to patients aged ≥65 \[[@pone.0217406.ref025], [@pone.0217406.ref034], [@pone.0217406.ref038], [@pone.0217406.ref042], [@pone.0217406.ref043]\]
  **PIM: considering diagnoses or conditions**      Medication/classes that is potentially prescribed inappropriately with a specific diagnose or condition.   Prescribing antipsychotics for patients with dementia and aged ≥65 \[[@pone.0217406.ref034]\]
  **DDI**                                           Medication/classes that is potentially interacts with another medication/class                             Prescribing antipsychotics with antiparkinsonian for patients aged ≥65 \[[@pone.0217406.ref044]\]
  **Inappropriate dosing**                          Medication that was prescribed in inappropriate dose                                                       Prescribing Haloperidol at a dose \>2 mg for patients aged ≥65 \[[@pone.0217406.ref045]--[@pone.0217406.ref047]\]
  **Inappropriate duration**                        Medication/class that was prescribed in inappropriate duration                                             Prescribing antipsychotics for \>1 month to patients aged ≥65 \[[@pone.0217406.ref048]\]
  **Inadequate monitoring**                         Medications/class that was not monitored adequately                                                        Prescribing lithium without monitoring lithium level every 6 months \[[@pone.0217406.ref010], [@pone.0217406.ref049], [@pone.0217406.ref050]\]
  **Omission**                                      Medication/class that should be prescribed with a specific diagnose or condition.                          Patients diagnosed with mild-moderate Alzheimer's dementia and aged ≥65 and were not prescribed acetylcholinesterase inhibitor \[[@pone.0217406.ref025]\]

DDI = drug-drug interaction. PIM = Potentially inappropriate medication.

Stage 3: Selecting potential PSIs related to MH disorders and medications {#sec017}
-------------------------------------------------------------------------

Following the identification and extraction of all mental health related indicators as described in the second stage, two experienced mental health pharmacists (RK and JN) together reviewed the identified list and used respected recourses, such as NICE guidelines \[[@pone.0217406.ref051]\], the Maudsley Prescribing Guidelines in Psychiatry \[[@pone.0217406.ref052]\], Psychotropic Drug Directory \[[@pone.0217406.ref053]\], Stockley's Drug Interactions \[[@pone.0217406.ref035]\] and the resources described in stage two along with their clinical knowledge to select potential PSIs that met our adapted \[[@pone.0217406.ref010]\] definition: statements that described a pattern of potentially hazardous prescribing or drug monitoring that could cause significant risk of harm. Our definition differed to the original in that we did not focus on prescribing specific to the UK and we did not consider data extraction feasibility due to the likelihood of different health care record/prescribing systems being used across the globe.

When selecting PSIs, if more than one indicator shared similar characteristics, the broader indicator was selected. For example, if an indicator was found for a class of medication but other indicators for specific medications existed within that class, only the former was selected as PSI. Another example, an indicator for elderly versus an indicator for all ages. If the risk of harm was relevant for all populations, then the latter was selected. This step was performed to reduce the large number of identified PSIs by removing similar indicators with slight variations. PSIs were also categorised according to the type of prescribing problem and to their therapeutic class as described for general MH related indicators in stage two.

Data analysis {#sec018}
-------------

A descriptive analysis of the findings was presented. The extracted information was presented in tabular form. Numbers and percentages were calculated when appropriate. In addition, the average number of reported indicators and standard deviation were provided.

Results {#sec019}
=======

Stage 1: Identifying studies that reported prescribing indicators of any kind {#sec020}
-----------------------------------------------------------------------------

The database search process identified 22,773 citations. Of these, 9,715 studies were removed because of duplication. The remaining 13,058 citations were screened for eligibility, where 12,842 were subsequently excluded. Hence, 216 full texts were retrieved for in-depth review. Of these, 129 were excluded leaving 87 studies for inclusion. After reviewing the reference lists of included studies and relevant reviews a further 3 studies were included, bringing the final number of the eligible studies to 90. However, 11 studies \[[@pone.0217406.ref021], [@pone.0217406.ref023], [@pone.0217406.ref033], [@pone.0217406.ref040], [@pone.0217406.ref054]--[@pone.0217406.ref060]\] were older versions of new articles, and only their most recent versions were included. Therefore, 79 unique studies were included in the analysis. A summary of the review process is shown in [Fig 2](#pone.0217406.g002){ref-type="fig"}. [Table 2](#pone.0217406.t002){ref-type="table"} summarises the information extracted from each included study. [Table 3](#pone.0217406.t003){ref-type="table"} summarises the characteristics of the 79 unique studies.

![Flow diagram of the review process.\
MH = Mental health. PSI = Prescribing Safety Indicators.](pone.0217406.g002){#pone.0217406.g002}

10.1371/journal.pone.0217406.t002

###### Summary of each included study.

![](pone.0217406.t002){#pone.0217406.t002g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author\                                                              Targeted Country(s)   Targeted Setting   Targeted Population                    Indicators Source                                                                                           Validation Method                 Type of Criteria/Indicators   No. of indicators                                     No. of MH indicators   
  Year                                                                                                                                                                                                                                                                                                                                                                                                          
  -------------------------------------------------------------------- --------------------- ------------------ -------------------------------------- ----------------------------------------------------------------------------------------------------------- --------------------------------- ----------------------------- ----------------------------------------------------- ---------------------- -----
  **AGS**\                                                             USA                   MS                 Elderly                                Literature review + older version \[[@pone.0217406.ref056]\]                                                Delphi^M^                         P                             PIM, DDI, DSI                                         231                    125
  2015 \[[@pone.0217406.ref034]\]                                                                                                                                                                                                                                                                                                                                                                               

  **[Older versions]{.ul} Beers** 1991 \[[@pone.0217406.ref054]\]\                                                                                                                                                                                                                                                                                                                                              
  **Beers** 1997 \[[@pone.0217406.ref055]\]\                                                                                                                                                                                                                                                                                                                                                                    
  **Fick** 2003 \[[@pone.0217406.ref040]\]\                                                                                                                                                                                                                                                                                                                                                                     
  **AGS** 2012 \[[@pone.0217406.ref056]\]                                                                                                                                                                                                                                                                                                                                                                       

  **Al-Taweel**\                                                       International         MS                 Adults with Bipolar disorder           Guidelines                                                                                                  NS consensus                      P                             Adherence to management guidelines                    26                     26
  2017 \[[@pone.0217406.ref049]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Alldred**\                                                         UK                    LTC                Elderly                                Guidelines + experience                                                                                     NS consensus                      P                             Medication monitoring errors                          25                     3
  2008 \[[@pone.0217406.ref061]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Avery**\                                                           UK                    Community          NS                                     NR                                                                                                          NR                                P                             Hazardous prescribing and inadequate monitoring       10                     1
  2009 \[[@pone.0217406.ref017]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Barnett**\                                                         UK                    Community          NS                                     Selected previously published studies                                                                       NS consensus                      P                             High risk prescribing                                 6                      1
  2014 \[[@pone.0217406.ref062]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Barry**\                                                           UK and Ireland        Community          Paediatric                             Literature review                                                                                           Delphi^M^                         P                             PIP                                                   12                     0
  2016 \[[@pone.0217406.ref063]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Basger**\                                                          Australia             MS                 Elderly                                Older version \[[@pone.0217406.ref023]\]                                                                    RAM                               P                             DRPs (Prescribing appropriateness)                    41                     6
  2012 \[[@pone.0217406.ref064]\]                                                                                                                                                                                                                                                                                                                                                                               

  **[Older version]{.ul} Basger** 2008 \[[@pone.0217406.ref023]\]                                                                                                                                                                                                                                                                                                                                               

  **Castillo-Páramo**\                                                 Spain                 Community          Elderly                                STOPP / START 2008 \[[@pone.0217406.ref059]\]                                                               RAM                               P                             PIM, PPO                                              86                     21
  2013 \[[@pone.0217406.ref043]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Caughey**\                                                         Australia             Hospitals          NS                                     Literature review                                                                                           RAM^M^                                                          Preventable medication-related hospitalisations       29                     1
  2014 \[[@pone.0217406.ref065]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Chang**\                                                           Taiwan                MS                 Elderly                                Selected previously published studies                                                                       Delphi^M^                         P                             PIM, DSI                                              182                    68
  2012 \[[@pone.0217406.ref066]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Chen**\                                                            UK                    Community          NS                                     Textbooks                                                                                                   NR                                P                             DDI, DSI                                              213                    NR
  2005 \[[@pone.0217406.ref067]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Clyne**\                                                           Ireland               Community          Elderly                                Selected previously published studies                                                                       NS consensus                      P                             PIP                                                   39                     14
  2013 \[[@pone.0217406.ref068]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Constantine**\                                                     USA                   NS                 All ages                               Guidelines                                                                                                  Expert Panel                      P                             Unusual prescribing                                   12                     10
  2013 \[[@pone.0217406.ref069]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Cooper**\                                                          UK and Ireland        NS                 Middle aged                            Selected previously published studies + Experience                                                          Delphi                            P                             PIP                                                   22                     7
  2014 \[[@pone.0217406.ref070]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Desnoyer**\                                                        International         Hospitals          Adults                                 Literature review + Experience                                                                              Delphi                            P                             PIM                                                   160                    22
  2017 \[[@pone.0217406.ref071]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Desrochers**\                                                      Canada                Pharmacies         CKD patients                           Literature review + Experience                                                                              RAM                               P                             DRPs                                                  50                     2
  2011 \[[@pone.0217406.ref072]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Dreischulte**\                                                     UK                    Community          NS                                     Literature review                                                                                           RAM^M^                            P                             High risk and suboptimal prescribing and monitoring   176                    16
  2012 \[[@pone.0217406.ref073]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Elliott**\                                                         Australia             Hospitals          Elderly                                Selected Previously published studies + Experience                                                          Expert panel                      P                             PQ (Prescribing appropriateness)                      19                     3
  2001 \[[@pone.0217406.ref074]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Fernández Urrusuno**\                                              Spain                 Community          NS                                     Guidelines                                                                                                  NGT                               P                             PQ                                                    14                     1
  2013 \[[@pone.0217406.ref075]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Fialová**\                                                         Czech                 NS                 Elderly                                Literature review                                                                                           Delphi^M^                         P                             PIM, DSI                                              121                    48
  2013 \[[@pone.0217406.ref047]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Fox**\                                                             UK                    Hospitals          Paediatric                             Thomas study \[[@pone.0217406.ref015]\] + Literature review + Local and national incidents + NPSA alerts    Delphi                            P                             PE (high risk prescribing)                            41                     0
  2016 \[[@pone.0217406.ref076]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Galán Retamal**\                                                   Spain                 Hospitals          Elderly                                Selected previously published studies                                                                       Delphi                            P                             PIM                                                   50                     15
  2014 \[[@pone.0217406.ref077]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Guerreiro**\                                                       Portugal              Community          NS                                     Selected previously published studies                                                                       Delphi                            P                             PDRM                                                  35                     4
  2007 \[[@pone.0217406.ref050]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Guthrie**\                                                         UK                    Community          NS                                     Literature review                                                                                           RAM^M^                            P                             High risk (Hazardous) prescribing                     9                      2
  2011 \[[@pone.0217406.ref011]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Hanora Lavan**\                                                    Ireland               MS                 Elderly with Limited life expectancy   Literature review + Experience                                                                              Delphi                            P                             PIP or PIM                                            27                     2
  2017 \[[@pone.0217406.ref078]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Harper**\                                                          USA                   Hospitals          Paediatric                             NR                                                                                                          NS consensus                      P                             DDI                                                   19                     7
  2014 \[[@pone.0217406.ref079]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Holmes**\                                                          USA                   LTC                Palliative with advanced dementia      Textbooks                                                                                                   Delphi^M^                         P                             Medication appropriateness categories                 54                     54
  2008 \[[@pone.0217406.ref080]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Holt**\                                                            Germany               NS                 Elderly                                Literature review + selected previously published studies                                                   Delphi^M^                         P                             PIM                                                   83                     51
  2010 \[[@pone.0217406.ref045]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Hurley**\                                                          USA                   Community          Adults                                 Textbooks + FDA black box warnings + Guidelines                                                             NR                                P                             Medication monitoring                                 24                     11
  2005 \[[@pone.0217406.ref081]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Khodyakov**\                                                       USA                   LTC                Elderly                                STOPP/START 2015 \[[@pone.0217406.ref025]\]                                                                 Delphi^M^                         P                             PIM, PPO                                              24                     9
  2017 \[[@pone.0217406.ref032]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Kim**\                                                             Korea                 Community          NS                                     WHO-ATC classification + the Korean National Health Insurance criteria for pharmacy benefits + guidelines   Delphi                            P                             Duplication                                           33                     0
  2015 \[[@pone.0217406.ref082]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Kim**\                                                             Korea                 NS                 Elderly                                Selected previously published studies                                                                       Delphi                            P                             PIM (DSI)                                             26                     18
  2015 \[[@pone.0217406.ref083]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Kim**\                                                             Korea                 MS                 Elderly                                Selected previously published studies + Older version                                                       Delphi^M^                         P                             PIM                                                   110                    54
  2018 \[[@pone.0217406.ref084]\]                                                                                                                                                                                                                                                                                                                                                                               

  **[Older version]{.ul}**\                                                                                                                                                                                                                                                                                                                                                                                     
  **Kim** 2010 \[[@pone.0217406.ref060]\]                                                                                                                                                                                                                                                                                                                                                                       

  **Kojima**\                                                          Japan                 NS                 Elderly                                Literature review                                                                                           NS consensus                      P                             PIM, PPO                                              37                     9
  2016 \[[@pone.0217406.ref085]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Kroger**\                                                          Canada                LTC                Patients with severe dementia          Literature Review                                                                                           RAM^M^                            P                             Medication appropriateness categories                 49                     49
  2015 \[[@pone.0217406.ref086]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Laroche**\                                                         France                NS                 Elderly                                Literature review                                                                                           Delphi                            P                             PIM                                                   34                     19
  2007 \[[@pone.0217406.ref087]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Lindblad**\                                                        USA                   Community          Elderly                                Literature Review                                                                                           Delphi                            P                             DSI                                                   28                     19
  2006 \[[@pone.0217406.ref088]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Mackinnon**\                                                       USA and Canada        NS                 Elderly                                Literature Review                                                                                           Delphi                            O                             PDRM                                                  52                     17
  2002 \[[@pone.0217406.ref038]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Maio**\                                                            Italy                 Community          Elderly                                Beers 2003 \[[@pone.0217406.ref040]\]                                                                       NGT                               P                             PIP                                                   23                     5
  2010 \[[@pone.0217406.ref031]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Malone**\                                                          USA                   Pharmacies         NS                                     Literature Review + DDI resources                                                                           Delphi^M^                         P                             DDI                                                   25                     11
  2004 \[[@pone.0217406.ref089]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Mann**\                                                            Austria               MS                 Elderly                                PRISCUS preliminary list                                                                                    Delphi^M^                         P                             PIM                                                   73                     37
  2012 \[[@pone.0217406.ref090]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Marzi**\                                                           Argentina             NS                 Elderly                                Literature review + selected previously published studies                                                   Delphi                            P                             PIM                                                   128                    63
  2018 \[[@pone.0217406.ref091]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Mast**\                                                            Netherlands           Community          Elderly                                Literature review + guidelines + experience                                                                 Delphi                            P                             DRPs                                                  124                    16
  2015 \[[@pone.0217406.ref092]\]                                                                                                                                                                                                                                                                                                                                                                               

  **McLeod**\                                                          Canada                NS                 Elderly                                Textbooks + Beers 1991 \[[@pone.0217406.ref054]\]                                                           Delphi^M^                         P                             PIP                                                   38                     14
  1997 \[[@pone.0217406.ref093]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Morris**\                                                          UK                    Community          NS                                     Older version + Selected previously published studies                                                       Delphi                            O                             PDRM                                                  24                     0
  2003 \[[@pone.0217406.ref094]\]                                                                                                                                                                                                                                                                                                                                                                               

  **[Older version]{.ul} Morris** 2002 \[[@pone.0217406.ref057]\]                                                                                                                                                                                                                                                                                                                                               

  **Nyborg**\                                                          Norway                LTC                Elderly                                NORGEP criteria \[[@pone.0217406.ref096]\] + Literature review + Experience.                                Delphi                            P                             PIM                                                   34                     17
  2015 \[[@pone.0217406.ref095]\]                                                                                                                                                                                                                                                                                                                                                                               

  **O\'Mahony**\                                                       Europe                MS                 Elderly                                Older version \[[@pone.0217406.ref059]\] + Literature review + Experience.                                  Delphi                            P                             PIM, PPO                                              114                    25
  2015 \[[@pone.0217406.ref025]\]                                                                                                                                                                                                                                                                                                                                                                               

  **[Older version]{.ul} Gallagher** 2008 \[[@pone.0217406.ref059]\]                                                                                                                                                                                                                                                                                                                                            

  **Oborne**\                                                          UK                    Hospitals          Elderly                                Literature Review                                                                                           Expert panel                      P                             Harmful and appropriate Prescribing                   14                     0
  1997 \[[@pone.0217406.ref097]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Oborne**\                                                          UK                    LTC                Elderly                                Selected previously published studies                                                                       NR                                P                             Harmful and Appropriate Prescribing                   13                     0
  2003 \[[@pone.0217406.ref098]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Okechukwu**\                                                       Ireland               Community          NS                                     Literature Review                                                                                           NS consensus                      P                             PQ                                                    11                     1
  2006 \[[@pone.0217406.ref099]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Onder**\                                                           Italy                 NS                 Elderly                                Literature Review                                                                                           Delphi^M^                         P                             Poor Prescribing Quality                              13                     1
  2014 \[[@pone.0217406.ref044]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Onder**\                                                           International         MS                 Complex Elderly                        Literature review + Guidelines                                                                              NS consensus                      P                             Recommendations to Prescribe                          19                     0
  2014 \[[@pone.0217406.ref100]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Paton**\                                                           UK                    Hospitals          Psychiatric patients                   NR                                                                                                          NR                                P                             PQ                                                    7                      5
  2004 \[[@pone.0217406.ref022]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Pazan**\                                                           Europe                NS                 Elderly                                Older version \[[@pone.0217406.ref058]\]                                                                    Delphi                            P                             Medication appropriateness categories                 264                    63
  2018 \[[@pone.0217406.ref101]\]                                                                                                                                                                                                                                                                                                                                                                               

  **[Older version]{.ul}**\                                                                                                                                                                                                                                                                                                                                                                                     
  **Kuhn-Thiel** 2014 \[[@pone.0217406.ref058]\]\                                                                                                                                                                                                                                                                                                                                                               
  Pazan 2016 \[[@pone.0217406.ref033]\]                                                                                                                                                                                                                                                                                                                                                                         

  **Phansalkar**\                                                      USA                   Pharmacies         NS                                     Selected previously published studies + Medications databases                                               NS consensus                      P                             DDI                                                   15                     7
  2011 \[[@pone.0217406.ref102]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Prot-labarthe**\                                                   France                NS                 Paediatric                             Literature Review                                                                                           Delphi                            P                             PIM, PPO                                              102                    9
  2014 \[[@pone.0217406.ref103]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Quintense**\                                                       Belgium               Hospitals          NS                                     Literature review + Guidelines                                                                              Expert panel                      P                             Clinical rules                                        78                     8
  2019 \[[@pone.0217406.ref104]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Rancourt**\                                                        Canada                LTC                Elderly                                Literature Review                                                                                           Delphi^M^                         P                             PIP                                                   111                    53
  2004 \[[@pone.0217406.ref041]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Raebel**\                                                          USA                   Community          NS                                     FDA black-box warnings + Guidelines + Experience                                                            NR                                P                             Medication monitoring                                 12                     2
  2006 \[[@pone.0217406.ref105]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Reabel**\                                                          USA                   Community          Elderly                                Selected previously published studies                                                                       Expert panel                      P                             PIM                                                   11                     5
  2007 \[[@pone.0217406.ref106]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Renom-Guiteras**\                                                  Europe                NS                 Elderly                                Selected previously published studies                                                                       Delphi                            P                             PIM                                                   282                    127
  2015 \[[@pone.0217406.ref046]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Robertson**\                                                       Canada                NS                 Elderly                                Mackinnon study \[[@pone.0217406.ref038]\] + Experience                                                     Delphi and NGT                    O                             PDRM                                                  52                     15
  2002 \[[@pone.0217406.ref107]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Rognstad**\                                                        Norway                Community          Elderly                                Literature Review + Experience                                                                              Delphi^M^                         P                             PIP (PIM, DDI)                                        36                     22
  2009 \[[@pone.0217406.ref096]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Ruths**\                                                           Norway                LTC                Elderly                                Literature Review + Guidelines + Experience                                                                 Expert panel                      P                             DRPs                                                  17                     7
  2003 \[[@pone.0217406.ref108]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Saverno**\                                                         USA                   Pharmacies         NS                                     Literature Review + DDI references                                                                          Consensus among the researchers   P                             DDI                                                   13                     1
  2011 \[[@pone.0217406.ref109]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Smits**\                                                           Netherlands           MS                 CKD patients                           Guidelines + Literature review                                                                              RAM                               P                             Optimal and unsafe prescribing                        16                     0
  2016 \[[@pone.0217406.ref110]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Solberg**\                                                         USA                   Community          Adults                                 3 key DDI references                                                                                        Expert panel                      P                             DDI                                                   44                     17
  2004 \[[@pone.0217406.ref111]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Spencer**\                                                         UK                    Community          NS                                     Literature review + older version \[[@pone.0217406.ref021]\] + Textbooks                                    RAM                               P                             Hazardous prescribing and inadequate monitoring.      56                     7
  2014 \[[@pone.0217406.ref010]\]                                                                                                                                                                                                                                                                                                                                                                               

  **[Older version]{.ul} Avery** 2011 \[[@pone.0217406.ref021]\]                                                                                                                                                                                                                                                                                                                                                

  **Tamblyn**\                                                         Canada                MS                 Elderly                                Literature Review + Experience + Textbooks                                                                  Expert panel                      P                             High risk prescribing and DDI                         32                     17
  1994 \[[@pone.0217406.ref112]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Thomas**\                                                          UK                    Hospitals          NS                                     literature review + Experience                                                                              Delphi                            P                             PE (high risk prescribing)                            80                     18
  2013 \[[@pone.0217406.ref015]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Tjia**\                                                            USA                   Community          Adults                                 Literature Review + FDA black-box warnings + Guidelines                                                     Delphi^M^                         P                             Medication monitoring                                 61                     13
  2010 \[[@pone.0217406.ref113]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Tommelein**\                                                       Belgium               Pharmacies         Elderly                                Literature Review                                                                                           RAM                               P                             PIP                                                   83                     18
  2015 \[[@pone.0217406.ref048]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Van der Linden**\                                                  Belgium               NS                 Elderly                                STOPP 2008 \[[@pone.0217406.ref059]\]                                                                       NS consensus                      P                             PIP                                                   76                     11
  2014 \[[@pone.0217406.ref042]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Van Dijk**\                                                        Netherlands           LTC                Elderly                                NR                                                                                                          NR                                P                             Suboptimal prescribing                                17                     1
  2003 \[[@pone.0217406.ref114]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Wessell**\                                                         USA                   Community          Adults                                 Literature Review                                                                                           NS consensus                      P                             Prescribing and Monitoring errors                     30                     8
  2010 \[[@pone.0217406.ref039]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Williams**\                                                        Ireland               Community          NS                                     Literature Review                                                                                           NS consensus                      P                             Harmful and Appropriate Prescribing                   16                     1
  2005 \[[@pone.0217406.ref115]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Winit Watjana**\                                                   Thailand              NS                 Elderly                                Literature Review + Textbooks                                                                               Delphi                            P                             High-risk medications, DDI and DSI                    77                     28
  2008 \[[@pone.0217406.ref116]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Yu**\                                                              USA                   Hospitals          NS                                     Literature Review + Experience                                                                              Delphi^M^                         P                             Medication monitoring                                 24                     1
  2011 \[[@pone.0217406.ref117]\]                                                                                                                                                                                                                                                                                                                                                                               

  **Zhan**\                                                            USA                   Community          Elderly                                Beers 1997 \[[@pone.0217406.ref055]\]                                                                       Delphi^M^                         P                             PIM                                                   33                     17
  2001 \[[@pone.0217406.ref118]\]                                                                                                                                                                                                                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ATC: The Anatomical, Therapeutic and Chemical. CKD: Chronic kidney disease. DDI: drug-drug interaction. DRPs: Drug related problems. DSI: drug-disease interaction. FDA: Food and Drug Administration. LTC: Long-term care. ^M^: Modified. MH: Mental Health. NGT: Nominal group technique. NORGEP: The Norwegian General Practice. NPSA: National Patient Safety Agency. NR = not reported. NS = not specified. O = Outcome (outcome indicator is the consequences of provided healthcare). P = Process (process indicators comprises the care provided to the patients). P/O = Process/Outcome. PDRM: preventable drug related morbidity. PE: prescribing errors. PIM: potentially inappropriate medication. PIP: potentially inappropriate prescribing. PPO: potentially prescribing omission. PQ: prescribing quality. RAM: RAND/UCLA Appropriateness Method. STOPP/START: Screening tool of older people\'s prescriptions and screening tool to alert to right treatment. UK: United Kingdom. USA: United States of America. WHO: World Health Organization.

10.1371/journal.pone.0217406.t003

###### Summary of included study characteristics.

![](pone.0217406.t003){#pone.0217406.t003g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                                              All unique studies             Studies included MH-related indicators                          Studies MH-related potential PSIs were selected from
  ---------------------------------------------------------------------------- ------------------------------ --------------------------------------------------------------- ----------------------------------------------------------------
  ***Continent***                                                                                                                                                             

  Europe                                                                       42 (53.2%)                     35 (50.0%)                                                      27 (47.5%)

  North America                                                                24 (30.4%)                     24 (34.3%)                                                      22 (37.3%)

  Asia                                                                         6 (67.7%)                      5 (7.1%)                                                        5 (8.5%)

  International                                                                3 (3.8%)                       2 (2.9%)                                                        2 (3.4%)

  Australia                                                                    3 (3.8%)                       3 (4.3%)                                                        1 (1.7%)

  South America                                                                1 (1.3%)                       1 (1.4%)                                                        1 (1.7%)

  ***Publication Year***                                                                                                                                                      

  1990--1999                                                                   3 (3.8%)                       2 (2.9%)                                                        2 (3.4%)

  2000--2009                                                                   26 (32.9%)                     23 (32.9%)                                                      18 (30.5%)

  2010--2019                                                                   47 (63.3%)                     45 (64.3%)                                                      39 (66.1%)

  ***Targeted population***                                                                                                                                                   

  Elderly                                                                      40 (50.6%)                     38 (54.3%)                                                      31 (52.5%)

  Not specified                                                                20 (25.3%)                     17 (24.3%)                                                      15 (25.4%)

  Adults                                                                       5 (6.3%)                       5 (7.1%)                                                        5 (8.5%)

  Paediatric                                                                   4 (5.1%)                       2 (2.9%)                                                        2 (3.4%)

  CKD                                                                          2 (2.5%)                       1 (1.4%)                                                        1 (1.7%)

  All ages                                                                     1 (1.3%)                       1 (1.4%)                                                        1 (1.7%)

  Middle aged                                                                  1 (1.3%)                       1 (1.4%)                                                        1 (1.7%)

  Psychiatric                                                                  1 (1.3%)                       1 (1.4%)                                                        1 (1.7%)

  Adults with bipolar disorder                                                 1 (1.3%)                       1 (1.4%)                                                        1 (1.7%)

  Severe dementia                                                              1 (1.3%)                       1 (1.4%)                                                        1 (1.7%)

  Elderly with Limited life expectancy                                         1 (1.3%)                       1 (1.4%)                                                        \-

  Palliative with advanced dementia                                            1 (1.3%)                       1 (1.4%)                                                        \-

  Complex elderly                                                              1 (1.3%)                       \-                                                              \-

  ***Targeted setting***                                                                                                                                                      

  Community                                                                    26 (32.9%)                     22 (31.4%)                                                      19 (32.2%)

  Not specified                                                                17 (21.5%)                     17 (24.3%)                                                      16 (27.1%)

  Hospitals                                                                    11 (13.9%)                     9 (12.9%)                                                       8 (13.6%)

  Multiple settings                                                            11 (13.9%)                     9 (12.9%)                                                       6 (10.2%)

  Long-term care                                                               9 (11.4%)                      8 (11.4%)                                                       5 (8.5%)

  Pharmacies                                                                   5 (6.3%)                       5 (7.1%)                                                        5 (8.5%)

  ***Methods to identify indicators*[^a^](#t003fn002){ref-type="table-fn"}**   **Reported 75 (94.9%)**        **Reported 66 (94.3%)**                                         **Reported 56 (94.9%)**

  Literature review                                                            41 (51.9%)                     36 (51.4%)                                                      33 (55.9%)

  Experience                                                                   16 (20.3%)                     16 (22.9%)                                                      13 (22.0%)

  Multiple selected tools [^b^](#t003fn003){ref-type="table-fn"}               16 (20.3%)                     14 (20.0%)                                                      11 (18.6%)

  Guidelines                                                                   12 (15.2%)                     9 (12.9%)                                                       8 (13.6%)

  Single selected tool [^c^](#t003fn004){ref-type="table-fn"}                  9 (11.4%)                      7 (10.0%)                                                       6 (10.2%)

  Textbooks [^d^](#t003fn005){ref-type="table-fn"}                             7 (8.9%)                       6 (8.6%)                                                        5 (8.5%)

  Older versions                                                               7 (8.9%)                       6 (8.6%)                                                        5 (8.5%)

  FDA black box warnings                                                       3 (3.8%)                       3 (4.3%)                                                        3 (5.1%)

  DDI references                                                               3 (3.8%)                       3 (4.3%)                                                        3 (5.1%)

  medication databases                                                         1 (1.3%)                       1 (1.4%)                                                        1 (1.7%)

  preliminary list                                                             1 (1.3%)                       1 (1.4%)                                                        \-

  Safety incidents                                                             1 (1.3%)                       \-                                                              \-

  ***Validation method***                                                      **Reported 72 (91.1%)**        **Reported 65 (92.9%)**                                         **Reported 55 (93.2%)**

  Delphi                                                                       38 (48.1%)                     34 (48.6%)                                                      29 (49.2%)

  NS consensus                                                                 12 (15.2%)                     11 (15.7%)                                                      10 (16.9%)

  RAM                                                                          10 (12.7%)                     9 (12.9%)                                                       8 (13.6%)

  Expert panel                                                                 8 (10.1%)                      7 (10.0%)                                                       5 (8.5%)

  NGT                                                                          2 (2.6%)                       2 (2.9%)                                                        1 (1.7%)

  Consensus among research group                                               1 (1.3%)                       1 (1.4%)                                                        1 (1.7%)

  Delphi and NGT                                                               1 (1.3%)                       1 (1.4%)                                                        1 (1.7%)

  ***Type of prescribing indicators***                                                                                                                                        

  Process                                                                      75 (94.9%)                     67 (95.7%)                                                      56 (94.9%)

  Outcome                                                                      4 (5.1%)                       3 (4.3%)                                                        3 (5.1%)

  ***Number of indicators***                                                   **4507 reported indicators**   **1386 MH related indicators**\                                 **245 MH related PSIs** [^e^](#t003fn006){ref-type="table-fn"}
                                                                                                              **(1106 after removing duplicates and splitting indicators)**   

  Average (SD)                                                                 57 (SD = 59.8)                 20 (SD = 25.1)                                                  \-

  Range                                                                        6--282                         1--127                                                          \-
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CKD: Chronic kidney disease. DDI: Drug-drug interactions. FDA: Food and Drug Administration. MH: Mental health. NGT: nominal group technique. NS: not specified. PSIs: Prescribing safety indicators. RAM: RAND/UCLA Appropriateness Method. SD: Standard deviation

^**a**^. The total percentage exceed 100% because most studies used more than one method.

^**b**^. These studies selected multiple previously published tools.

^**c**^. These studies selected one specific tool

^**d**^. These studies used selected textbooks.

^**e**^. The average, SD and range were not calculated for the potential PSIs because they were selected after removing duplicates and splitting indicators.

Stage 2: Identifying and extracting MH related prescribing indicators {#sec021}
---------------------------------------------------------------------

From the 79 included unique studies, a total of 4507 individual prescribing indicators were reported containing an average of 57 (SD = 59.8) indicators per study, ranging from 6 \[[@pone.0217406.ref062]\] to 282 \[[@pone.0217406.ref046]\] indicators.

Seventy studies (88.6% of unique studies) contained at least one mental health related indicator. Following data extraction and review, a total of 1386 (30.8% of total) indicators were deemed to be mental health related based on our operational definition ([Box 1](#pone.0217406.box001){ref-type="boxed-text"}). There was an average of 20 (SD = 25.1) mental health related indicators per study, and ranging from 1 \[[@pone.0217406.ref017], [@pone.0217406.ref044], [@pone.0217406.ref062], [@pone.0217406.ref065], [@pone.0217406.ref075], [@pone.0217406.ref099], [@pone.0217406.ref109], [@pone.0217406.ref114], [@pone.0217406.ref115], [@pone.0217406.ref117]\] to 127 \[[@pone.0217406.ref046]\] indicators. Five studies were concerned exclusively with prescribing indicators in the mental health population/setting \[[@pone.0217406.ref022], [@pone.0217406.ref049], [@pone.0217406.ref069], [@pone.0217406.ref080], [@pone.0217406.ref086]\]. Nine studies did not report any mental health prescribing indicators \[[@pone.0217406.ref063], [@pone.0217406.ref067], [@pone.0217406.ref076], [@pone.0217406.ref082], [@pone.0217406.ref094], [@pone.0217406.ref097], [@pone.0217406.ref098], [@pone.0217406.ref100], [@pone.0217406.ref110]\]. [Table 3](#pone.0217406.t003){ref-type="table"} summarises the characteristics of the studies that included mental health related prescribing indicators (n = 70).

### Countries {#sec022}

Most studies developed prescribing indicator tools to be used in the United States of America (USA) \[[@pone.0217406.ref032], [@pone.0217406.ref034], [@pone.0217406.ref039], [@pone.0217406.ref069], [@pone.0217406.ref079]--[@pone.0217406.ref081], [@pone.0217406.ref088], [@pone.0217406.ref089], [@pone.0217406.ref102], [@pone.0217406.ref105], [@pone.0217406.ref106], [@pone.0217406.ref109], [@pone.0217406.ref111], [@pone.0217406.ref113], [@pone.0217406.ref117], [@pone.0217406.ref118]\] (n = 17/70, 24.3%), followed by the United Kingdom (UK) \[[@pone.0217406.ref010], [@pone.0217406.ref011], [@pone.0217406.ref015], [@pone.0217406.ref017], [@pone.0217406.ref022], [@pone.0217406.ref061], [@pone.0217406.ref062], [@pone.0217406.ref073]\] (n = 8, 11.4%) and Canada \[[@pone.0217406.ref041], [@pone.0217406.ref072], [@pone.0217406.ref086], [@pone.0217406.ref093], [@pone.0217406.ref107], [@pone.0217406.ref112]\] (n = 6, 8.6%). The remaining studies described tools developed for Ireland \[[@pone.0217406.ref068], [@pone.0217406.ref078], [@pone.0217406.ref099], [@pone.0217406.ref115]\] (n = 4, 5.7%), Spain \[[@pone.0217406.ref043], [@pone.0217406.ref075], [@pone.0217406.ref077]\] (n = 3, 4.3%), Australia \[[@pone.0217406.ref064], [@pone.0217406.ref065], [@pone.0217406.ref074]\] (n = 3, 4.3%), Norway \[[@pone.0217406.ref095], [@pone.0217406.ref096], [@pone.0217406.ref108]\] (n = 3, 4.3%), Belgium \[[@pone.0217406.ref042], [@pone.0217406.ref048], [@pone.0217406.ref104]\] (n = 3, 4.3%), The Netherlands \[[@pone.0217406.ref092], [@pone.0217406.ref114]\] (n = 2, 2.9%), Italy \[[@pone.0217406.ref031], [@pone.0217406.ref044]\] (n = 2, 2.9%), France \[[@pone.0217406.ref087], [@pone.0217406.ref103]\] (n = 2, 2.9%), Korea \[[@pone.0217406.ref083], [@pone.0217406.ref084]\] (n = 2, 2.9%), Germany \[[@pone.0217406.ref045]\] (n = 1, 1.4%), Taiwan \[[@pone.0217406.ref066]\] (n = 1, 1.4%), Austria \[[@pone.0217406.ref090]\] (n = 1, 1.4%), the Czech Republic \[[@pone.0217406.ref047]\] (n = 1, 1.4%), Portugal \[[@pone.0217406.ref050]\] (n = 1, 1.4%), Japan \[[@pone.0217406.ref085]\] (n = 1, 1.4%), Argentina \[[@pone.0217406.ref091]\] (n = 1, 1.4%) and Thailand \[[@pone.0217406.ref116]\] (n = 1, 1.5%). Another 7 studies developed tools to be used in more than one country; 3 (4.3%) \[[@pone.0217406.ref025], [@pone.0217406.ref046], [@pone.0217406.ref101]\] were for European countries, 2 (2.9%) \[[@pone.0217406.ref049], [@pone.0217406.ref071]\] were for international use, 1 (1.4%) \[[@pone.0217406.ref070]\] were for the UK and Ireland, and 1 (1.4%) \[[@pone.0217406.ref038]\] was for Canada and the USA.

### Publication year {#sec023}

Only 2 studies (2.9%) \[[@pone.0217406.ref093], [@pone.0217406.ref112]\] were published prior to the year 2000. A total of 23 (32.9%) studies were published between 2000--2009, and 45 (64.3%) from 2010 onwards.

### Targeted population {#sec024}

The elderly population was the most common patient group specifically targeted by the indicator tools (n = 38/70, 54.3%). Of these, 26/38 (68.4%) \[[@pone.0217406.ref025], [@pone.0217406.ref031], [@pone.0217406.ref032], [@pone.0217406.ref034], [@pone.0217406.ref041], [@pone.0217406.ref043]--[@pone.0217406.ref047], [@pone.0217406.ref061], [@pone.0217406.ref064], [@pone.0217406.ref066], [@pone.0217406.ref074], [@pone.0217406.ref077], [@pone.0217406.ref083], [@pone.0217406.ref084], [@pone.0217406.ref088], [@pone.0217406.ref090], [@pone.0217406.ref092], [@pone.0217406.ref101], [@pone.0217406.ref106]--[@pone.0217406.ref108], [@pone.0217406.ref112], [@pone.0217406.ref118]\] studies defined their elderly population as ≥65 years old, 3 (7.9%) \[[@pone.0217406.ref068], [@pone.0217406.ref095], [@pone.0217406.ref096]\] as ≥70 years old, 2 (5.3%) \[[@pone.0217406.ref085], [@pone.0217406.ref087]\] as ≥75 years old, and the remaining 7 (18.4%) \[[@pone.0217406.ref038], [@pone.0217406.ref042], [@pone.0217406.ref048], [@pone.0217406.ref091], [@pone.0217406.ref093], [@pone.0217406.ref114], [@pone.0217406.ref116]\] tools did not define a specific age. Of the remaining studies, 5/70 (7.1%) \[[@pone.0217406.ref039], [@pone.0217406.ref071], [@pone.0217406.ref081], [@pone.0217406.ref111], [@pone.0217406.ref113]\] described tools specifically for adults, 2 (2.9%) \[[@pone.0217406.ref079], [@pone.0217406.ref103]\] for paediatric patients, 4 (5.7%) for psychiatric patients (including bipolar disorder (n = 1),\[[@pone.0217406.ref049]\] general psychiatric patients (n = 1)\[[@pone.0217406.ref022]\] and severe/advanced dementia (n = 2)\[[@pone.0217406.ref080], [@pone.0217406.ref086]\]), and 1 (1.4%) \[[@pone.0217406.ref072]\] for patients with chronic kidney disease. Another 3 indicator tools specifically targeted either middle age (45--46 years old) patients \[[@pone.0217406.ref070]\], patients of all ages \[[@pone.0217406.ref069]\] and patients with limited life expectancy \[[@pone.0217406.ref078]\]. A total of 17 (24.3%) \[[@pone.0217406.ref010], [@pone.0217406.ref015], [@pone.0217406.ref017], [@pone.0217406.ref050], [@pone.0217406.ref062], [@pone.0217406.ref065], [@pone.0217406.ref073], [@pone.0217406.ref075], [@pone.0217406.ref089], [@pone.0217406.ref099], [@pone.0217406.ref102], [@pone.0217406.ref104], [@pone.0217406.ref105], [@pone.0217406.ref109], [@pone.0217406.ref115], [@pone.0217406.ref117], [@pone.0217406.ref119]\] of the 70 studies did not identify a population that their indicators were meant to be applied to.

### Setting {#sec025}

A total of 22 (31.4%) studies developed tools that were specific to patients in the community, including primary care (n = 14, 20.0%)\[[@pone.0217406.ref010], [@pone.0217406.ref011], [@pone.0217406.ref017], [@pone.0217406.ref039], [@pone.0217406.ref043], [@pone.0217406.ref050], [@pone.0217406.ref062], [@pone.0217406.ref068], [@pone.0217406.ref073], [@pone.0217406.ref075], [@pone.0217406.ref092], [@pone.0217406.ref096], [@pone.0217406.ref099], [@pone.0217406.ref115]\], ambulatory care (n = 5, 7.1%) \[[@pone.0217406.ref081], [@pone.0217406.ref105], [@pone.0217406.ref106], [@pone.0217406.ref111], [@pone.0217406.ref113]\] and 3 studies (4.2%) \[[@pone.0217406.ref031], [@pone.0217406.ref088], [@pone.0217406.ref118]\] targeted any patients in the community.

Seventeen (24.3%) studies did not specify a setting for their developed tools. The remaining tools targeted hospitals (n = 9/70, 12.9%) \[[@pone.0217406.ref015], [@pone.0217406.ref022], [@pone.0217406.ref065], [@pone.0217406.ref071], [@pone.0217406.ref074], [@pone.0217406.ref077], [@pone.0217406.ref079], [@pone.0217406.ref104], [@pone.0217406.ref117]\], multiple settings (n = 9, 12.9%) \[[@pone.0217406.ref025], [@pone.0217406.ref034], [@pone.0217406.ref049], [@pone.0217406.ref064], [@pone.0217406.ref066], [@pone.0217406.ref078], [@pone.0217406.ref084], [@pone.0217406.ref090], [@pone.0217406.ref112]\], long-term care settings (n = 8, 11.8%) \[[@pone.0217406.ref032], [@pone.0217406.ref041], [@pone.0217406.ref061], [@pone.0217406.ref080], [@pone.0217406.ref086], [@pone.0217406.ref095], [@pone.0217406.ref108], [@pone.0217406.ref114]\] and pharmacies (n = 5, 7.1%) \[[@pone.0217406.ref048], [@pone.0217406.ref072], [@pone.0217406.ref089], [@pone.0217406.ref102], [@pone.0217406.ref109]\].

### Method to identify prescribing indicators {#sec026}

Methods used to identify indicators were reported in 66 (94.3%) of the studies. A total of 38 (54.3%) studies used one method to identify their prescribing indicators, with 28 (40.0%) using more than one method. Another 4 (5.7%) \[[@pone.0217406.ref017], [@pone.0217406.ref022], [@pone.0217406.ref079], [@pone.0217406.ref114]\] studies did not report a source of their indicators. Literature review was the most commonly method used, being used in 36 (51.4%) studies. Authors who provided additional detail described literature review processes as including searching for indicators from previously published tools and/or searching to identify new indicators from randomised controlled trials and observational studies.

Other reported sources of prescribing indicators included clinical experience (n = 16, 22.9%), selecting multiple previously published tools (n = 14, 20.0%) or a single tool (n = 7, 10.0%) (without mentioning literature review), guidelines (n = 9, 12.9%), textbooks (n = 6, 8.6%), older versions to be updated (n = 6, 8.6%), FDA black box warnings (n = 3, 4.3%), DDI references (n = 3, 4.3%), preliminary list of previous tool (n = 1, 1.4%) and medication databases (n = 1, 1.4%).

### Validation method {#sec027}

The most commonly used method for validation of prescribing indicators was the Delphi method, \[[@pone.0217406.ref120]\] which was used during development of 34 (48.6%) tools (of these, 16/34 (47.1%) used a modified Delphi). The RAND/UCLA appropriateness method (RAM) \[[@pone.0217406.ref121]\] was used in development of 9 tools (12.9%) \[[@pone.0217406.ref010], [@pone.0217406.ref011], [@pone.0217406.ref043], [@pone.0217406.ref048], [@pone.0217406.ref064], [@pone.0217406.ref065], [@pone.0217406.ref072], [@pone.0217406.ref073], [@pone.0217406.ref086]\] (of these, 4/9 (44.4%) \[[@pone.0217406.ref011], [@pone.0217406.ref065], [@pone.0217406.ref073], [@pone.0217406.ref086]\] used a modified RAM). Of the remaining studies, 7 (10.0%) \[[@pone.0217406.ref069], [@pone.0217406.ref074], [@pone.0217406.ref104], [@pone.0217406.ref106], [@pone.0217406.ref108], [@pone.0217406.ref111], [@pone.0217406.ref112]\] used an expert panel, 2 (2.9%) \[[@pone.0217406.ref031], [@pone.0217406.ref075]\] used the Nominal Group Technique (NGT), 1 (1.4%) \[[@pone.0217406.ref109]\] used consensus among the research group without further description and 1 (1.4%) \[[@pone.0217406.ref107]\] used both Delphi and NGT. A total of 11 (15.7%) \[[@pone.0217406.ref039], [@pone.0217406.ref042], [@pone.0217406.ref049], [@pone.0217406.ref061], [@pone.0217406.ref062], [@pone.0217406.ref068], [@pone.0217406.ref079], [@pone.0217406.ref085], [@pone.0217406.ref099], [@pone.0217406.ref102], [@pone.0217406.ref115]\] studies used a non-specific consensus building approach, and 5 (7.1%) \[[@pone.0217406.ref017], [@pone.0217406.ref022], [@pone.0217406.ref081], [@pone.0217406.ref105], [@pone.0217406.ref114]\] did not report any validation of their prescribing indicators.

### Type of prescribing indicators {#sec028}

A total of 67 (95.7%) studies developed prescribing process indicators. Numerous terms describing the prescribing processes of interest were used in the included studies. These included: hazardous, suboptimal, optimal, inappropriate, unsafe, high risk, omitted and unusual prescribing, prescribing appropriateness, drug-related problems (DRPs), adherence to management guidelines, PIM, high risk medication, DDI, drug disease interaction, inadequate monitoring and monitoring errors. The remaining 3 (4.3%) \[[@pone.0217406.ref038], [@pone.0217406.ref050], [@pone.0217406.ref107]\] studies developed prescribing outcome indicators to identify preventable drug related morbidity (PDRM) and preventable medication-related hospitalisations.

### Categorising MH related prescribing indicators {#sec029}

From the 1386 extracted mental health related indicators, duplicates were removed and some indicators were split and re-categorised by the research team, which reduced the final number of the included indicators to 1106. These indicators were categorised into eight types of prescribing problems and into nine medication categories. The full list of mental health related indicators can be found in [S2 File](#pone.0217406.s002){ref-type="supplementary-material"}.

For prescribing problems, the highest number of indicators were categorised under 'PIM: Considering Diagnoses or Conditions' which contained 447 (40.4%) indicators. This was followed by 'PIM: Independent of Diagnoses or Conditions' (n = 269, 24.3%), 'DDI' (n = 153, 13.8%), 'inappropriate duration' and 'inappropriate dose' (n = 74 each, 6.7%). The categories containing the fewest number of indicators were 'omission' with only 8 (0.7%) indicators, along with 'others' (n = 28, 2.5%) and 'monitoring' indicators (n = 53, 4.8%).

Medications classed under the sedative, hypnotic and anxiolytics group were the most commonly reported in the developed tools with 317 indicators (28.7%). This was followed by antidepressants (n = 241, 21.8%), antipsychotics (n = 191, 17.3%) and mood stabilisers (n = 88, 8.0%). The remaining categories were anticholinergics (n = 56, 5.1%), anti-dementia (n = 49, 4.4%) and ADHD medications (n = 24, 2.2%). Fifteen indicators (1.4%) included psychotropics without specifying a class. Furthermore, 125 (11.3%) indicators included non-mental health medications with mental health conditions. These conditions included delirium, insomnia, depression, dementia, advanced dementia, palliative advanced dementia and non-palliative dementia. [Table 4](#pone.0217406.t004){ref-type="table"} summarises the number of prescribing indicators in each category.

10.1371/journal.pone.0217406.t004

###### Numbers of prescribing indicators related to mental health in each prescribing problem and medication category.

![](pone.0217406.t004){#pone.0217406.t004g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Prescribing Problem                   PIM\                                     PIM\                                  DDI               Inappropriate Duration   Inappropriate Dose   Monitoring      Omission       Others          Total: n (%)
                                        Independent of Diagnoses or Conditions   Considering Diagnoses or Conditions                                                                                                                  
  ------------------------------------- ---------------------------------------- ------------------------------------- ----------------- ------------------------ -------------------- --------------- -------------- --------------- -----------------
  **Medication Category**                                                                                                                                                                                                             

  Antipsychotics                        45                                       85                                    13                19                       18                   7               0              4               **191 (17.3%)**

  Antidepressants                       42                                       102                                   67                9                        9                    0               4              8               **241 (21.8%)**

  Sedative, hypnotics and anxiolytics   119                                      75                                    36                40                       44                   3               0              0               **317 (28.7%)**

  Mood stabilisers                      2                                        10                                    22                0                        2                    42              2              8               **88 (8.0%)**

  Anti-dementia                         27                                       13                                    7                 0                        0                    0               2              0               **49 (4.4%)**

  ADHD medications                      8                                        13                                    1                 0                        1                    1               0              0               **24 (2.2%)**

  Anticholinergics                      26                                       24                                    2                 4                        0                    0               0              0               **56 (5.1%)**

  Non-Specific Psychotropics            0                                        1                                     5                 1                        0                    0               0              8               **15 (1.4%)**

  Non-MH medication with MH condition   0                                        124                                   0                 1                        0                    0               0              0               **125 (11.3%)**

  **Total: n (%)**                      **269 (24.3%)**                          **447 (40.4%)**                       **153 (13.8%)**   **74 (6.7%)**            **74 (6.7%)**        **53 (4.8%)**   **8 (0.7%)**   **28 (2.5%)**   **1106 (100%)**
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADHD: Attention deficit hyperactivity disorder. DDI: drug-drug interaction. MH: Mental Health. PIM: potentially inappropriate medication

Stage 3: Selecting potential PSIs related to MH disorders and medications {#sec030}
-------------------------------------------------------------------------

From the 1106 identified MH related indicators, 245 were considered to meet our PSI definition following review as they described prescribing or drug monitoring practices that could be hazardous and may put patients at significant risk of harm. These potential PSIs were selected from 59 studies out of the 70 that included MH related indicators. [Table 3](#pone.0217406.t003){ref-type="table"} summarises the characteristics of the studies that potential PSIs related to MH were selected from (n = 59).

### Categorising potential PSIs related to MH disorders and medications {#sec031}

Potential PSIs were categorised into eight types of prescribing problems. The highest number of indicators were categorised under 'PIM: Considering Diagnoses or Conditions' which contained 91 (37.1%) indicators. This was followed by 'DDI' (n = 66, 26.9%), 'inappropriate dose' (n = 24, 9.8%), 'PIM: Independent of Diagnoses or Conditions' (n = 20, 8.2%), 'monitoring' (n = 17, 6.9%), 'inappropriate duration' (n = 12, 4.9%), 'Other' (n = 10, 4.1%) and 'Omission' with only 5 (2.0%) indicators.

Potential PSI were also categorised into nine medication categories. Antidepressants were the most commonly selected with 85 (34.7%) potential PSIs. This was followed by sedative, hypnotic and anxiolytics (n = 50, 20.4%), antipsychotics (n = 38, 15.5%) and mood stabilisers (n = 33, 13.5%). The remaining were ADHD medications (n = 12, 4.9%), non-mental health medications with mental health conditions (n = 11, 4.5%), anticholinergics and anti-dementia (n = 7 each, 2.9%), and 2 indicators (0.8%) included psychotropics in general.

[Table 5](#pone.0217406.t005){ref-type="table"} summarises the number of potential PSIs in each category. [Table 6](#pone.0217406.t006){ref-type="table"} provides some examples of the selected potential PSIs. The full list can be found in [S3 File](#pone.0217406.s003){ref-type="supplementary-material"}.

10.1371/journal.pone.0217406.t005

###### Numbers of potential prescribing safety indicators related to mental health in each prescribing problem and medication category.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Prescribing Problem                   PIM\                                     PIM\                                  DDI              Inappropriate Duration   Inappropriate Dose   Monitoring      Omission       Others          Total: n (%)
                                        Independent of Diagnoses or Conditions   Considering Diagnoses or Conditions                                                                                                                 
  ------------------------------------- ---------------------------------------- ------------------------------------- ---------------- ------------------------ -------------------- --------------- -------------- --------------- ----------------
  **Medication Category**                                                                                                                                                                                                            

  Antipsychotics                        2                                        19                                    4                3                        3                    6               0              1               **38 (15.5%)**

  Antidepressants                       7                                        37                                    31               3                        3                    0               2              2               **85 (34.7%)**

  Sedative, hypnotics and anxiolytics   6                                        9                                     14               4                        17                   0               0              0               **50 (20.4%)**

  Mood stabilisers                      0                                        3                                     13               0                        0                    10              1              6               **33 (13.5%)**

  Anti-dementia                         0                                        3                                     2                0                        0                    0               2              0               **7 (2.9%)**

  ADHD medications                      4                                        5                                     1                0                        1                    1               0              0               **12 (4.9%)**

  Anticholinergics                      1                                        5                                     1                0                        0                    0               0              0               **7 (2.9%)**

  Non-Specific Psychotropics            0                                        0                                     0                1                        0                    0               0              1               **2 (0.8%)**

  Non-MH medication with MH condition   0                                        10                                    0                1                        0                    0               0              0               **11 (4.5%)**

  **Total: n (%)**                      **20 (8.2%)**                            **91 (37.1%)**                        **66 (26.9%)**   **12 (4.9%)**            **24 (9.8%)**        **17 (6.9%)**   **5 (2.0%)**   **10 (4.1%)**   **245 (100%)**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADHD: Attention deficit hyperactivity disorder. DDI: drug-drug interaction. MH: Mental Health. PIM: potentially inappropriate medication

10.1371/journal.pone.0217406.t006

###### Examples of the selected potential prescribing safety indicators.
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  Prescribing problem                               Medication category                           Example                                                                                                                        Sources
  ------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------
  **PIM: Independent of Diagnoses or Conditions**   ***Antidepressants***                         Prescribing tricyclic antidepressant to a patient aged ≥ 65 years                                                              \[[@pone.0217406.ref032], [@pone.0217406.ref034], [@pone.0217406.ref038], [@pone.0217406.ref065]\]
  **PIM: Considering diagnoses or conditions**      ***Antipsychotics***                          Prescribing antipsychotics other than quetiapine or clozapine to a patient aged ≥ 65 years with Parkinson's disease            \[[@pone.0217406.ref025], [@pone.0217406.ref032], [@pone.0217406.ref048], [@pone.0217406.ref073], [@pone.0217406.ref092]\]
  **DDI**                                           ***Anticholinergics***                        Prescribing two anticholinergics to a patient aged ≥ 65 years                                                                  \[[@pone.0217406.ref025], [@pone.0217406.ref032], [@pone.0217406.ref034], [@pone.0217406.ref048]\]
  **Inappropriate Duration**                        ***Sedative*, *hypnotics and anxiolytics***   Prescribing Benzodiazepine for more than 1 month                                                                               \[[@pone.0217406.ref015], [@pone.0217406.ref099]\]
  **Inappropriate dose**                            ***Antipsychotics***                          Prescribing high dose antipsychotics (*total daily dose is above the maximum recommended by the British National Formulary)*   \[[@pone.0217406.ref022]\]
  **Monitoring**                                    ***Mood stabilisers***                        Prescribing lithium without monitoring lithium plasma level every 3 months                                                     \[[@pone.0217406.ref017], [@pone.0217406.ref061]\]
  **Omission**                                      ***Antidepressants***                         Patients diagnosed with moderate/severe depressive symptoms lasting at least three months without prescribing antidepressant   \[[@pone.0217406.ref025]\]

DDI: drug-drug interaction. MH: Mental Health. PIM: potentially inappropriate medication.

Discussion {#sec032}
==========

To our knowledge, this is the first systemic review conducted to identify and screen all known published prescribing indicators and inappropriate prescribing tools in order to extract potential prescribing safety indicators (PSIs) related to populations with mental illness, and indeed any broader type of mental health related prescribing quality indicators. An earlier systematic review \[[@pone.0217406.ref020]\] published in 2014 was limited to inappropriate prescribing assessment tools, and another review by Song et al. \[[@pone.0217406.ref019]\] published in 2017 was limited to quality indicators and did not include most of the inappropriate prescribing tools which means that these reviews missed many studies which we found to contain potential PSIs and broader mental health related indicators, such as Gurerriro et al. in 2007 \[[@pone.0217406.ref050]\], Dreischulte et al. in 2012 \[[@pone.0217406.ref073]\] and Wessell et al. in 2010 \[[@pone.0217406.ref039]\].

We found 5 \[[@pone.0217406.ref022], [@pone.0217406.ref049], [@pone.0217406.ref069], [@pone.0217406.ref080], [@pone.0217406.ref086]\] studies specifically focused on developing/reporting prescribing indicators for populations with mental illness. However, two of these studies \[[@pone.0217406.ref080], [@pone.0217406.ref086]\] were exclusively for patients with dementia and one was for patients suffering with bipolar disorder \[[@pone.0217406.ref049]\]. Although 2 studies were found that involved development of prescribing indicators for a range of mental disorders and which contained some PSIs \[[@pone.0217406.ref022], [@pone.0217406.ref069]\], their main focus was not on safety and therefore they did not capture many hazardous prescribing issues, such as medication monitoring and omissions \[[@pone.0217406.ref022], [@pone.0217406.ref069]\].

It is clear from the findings that there has been an increase in the incidence of new explicit, patient-level data based suites of prescribing indicators being published for use across various patient populations over time. This might be a result of increased implementation of electronic health records worldwide \[[@pone.0217406.ref122]\] and the great improvements in the quality of these records which made operating electronic searches using prescribing indicators possible \[[@pone.0217406.ref123]\]. It also indicates an increasing emphasis on the quality and safety of healthcare, as noted in the wider literature \[[@pone.0217406.ref124]\]. A contributory factor to this rise might also be because indicators are used for audit and feedback purposes, which may be one of the more effective strategies to improve prescribing quality and quality of healthcare \[[@pone.0217406.ref125]\]. However, suites of prescribing indicators relevant to those with mental health illness have remained uncommon, and a specific suite of PSIs tailored to mental health illness and medications remains absent.

The methods used to identify indicators were reported in 94.3% of the studies reporting mental health related indicators, which is consistent with another systematic review that examined the development of general health care quality indicators using the Delphi method \[[@pone.0217406.ref126]\]. However, these methods varied significantly between the included studies, with some not reporting any sources for their indicators \[[@pone.0217406.ref017], [@pone.0217406.ref079], [@pone.0217406.ref080], [@pone.0217406.ref114]\], or using a single previously published study. In contrast, others conducted comprehensive systematic reviews of the relevant literature to identify previously published indicators or new potential indicators. Even though there is no agreed optimum method to identify/develop potential indicators reported in the literature, literature review was found to be the most commonly used method in this review and in a previous publication \[[@pone.0217406.ref126]\]. In addition, this method was also used by the Agency for Healthcare Research and Quality (AHRQ) to identify potential indicators \[[@pone.0217406.ref127]\]. Future research efforts should work towards building a consensus on the appropriate types and number of sources for the development of prescribing indicators, to guide researchers when developing new indicators.

Most studies reported a validation process with differences in approach and the depth of detail provided. The majority of studies used a consensus approach to validate their indicators. Each consensus method has its own advantages and disadvantages. However, there is a lack of standardisation in defining, using and reporting of consensus methods \[[@pone.0217406.ref128]\]. For example, some studies used modified Delphi and other used the RAM. However, the RAM can also be known as modified Delphi \[[@pone.0217406.ref121]\]. Therefore, it is important that studies report how the original method has been modified. Moreover, some studies did not specify which consensus method they used. In future it would be worthwhile to develop a method to assess the quality of implementation and reporting of consensus-based studies, and to develop a way to determine which method(s) might be most appropriate to apply for different prescribing indicators-based research projects based on their respective aims. A small number of studies did not report any process of validation for their indicators \[[@pone.0217406.ref017], [@pone.0217406.ref022], [@pone.0217406.ref067], [@pone.0217406.ref081], [@pone.0217406.ref099], [@pone.0217406.ref105], [@pone.0217406.ref108], [@pone.0217406.ref111], [@pone.0217406.ref112], [@pone.0217406.ref114], [@pone.0217406.ref115]\]. However, some of these studies did not aim to report the development of indicators such as the PINCER trial \[[@pone.0217406.ref017]\] which instead aimed to compare the effectiveness of an intervention and prescribing indicators were used as the outcome measure. Therefore, potential indicators retrieved from these studies require further validation.

This review has presented the number of all potential mental health related PSIs and broader mental health related prescribing indicators in each prescribing problem and in each therapeutic category. An expansive lists of different mental health related indicators has been identified. However, it is evident from the findings that some types of hazardous prescribing and therapeutic classes were under-represented in the published prescribing indicators and consequently in the selected potential PSIs. For instance, only 8 (0.7%) MH indicators and 5 (2.0%) potential PSIs for the category 'omission' were identified. Yet, it has been reported that omission is a predominant type of prescribing error in mental health hospitals \[[@pone.0217406.ref129], [@pone.0217406.ref130]\].

Likewise, monitoring indicators reported in the literature were mostly limited to mood stabilisers with few indicators for monitoring of antipsychotics, and no indicators for monitoring of antidepressants. As an example of potential PSIs that might have been missed include monitoring of liver function tests with agomelatine \[[@pone.0217406.ref131]\]. Additionally, more than two thirds of MH indicators and potential PSIs focused on antipsychotics, antidepressants and sedative-hypnotics. Conversely, other categories such as mood stabilisers, anti-dementia and ADHD medications, represented only 14.6% of the total number of indicators reported and 21.3% of the potential PSIs. This could suggest that these categories were marginalised in the literature and potential PSIs might have been missed.

Furthermore, the majority of the identified MH related indicators were developed for application to elderly populations, with a limited number of indicators designed for other populations such as younger people. Despite that evidence has shown that half of mental disorders start in childhood, and 75% by adolescence \[[@pone.0217406.ref132]\]. It is also found that in the UK about 1 in 10 children have a clinically diagnosable mental health problem \[[@pone.0217406.ref133]\]. Yet, 70% of those did not receive appropriate care \[[@pone.0217406.ref134]\]. In addition, no indicators have been reported for pregnant or breastfeeding women, despite the risk of some psychotropics in this group such as prescribing valproate in women of child bearing potential \[[@pone.0217406.ref135]\]. Consequently, it is important that future work takes the into consideration the unique characteristics of populations with mental illness, the different therapeutic classes of psychotropics and different prescribing problems when developing new suites of PSIs.

Based on our findings, none of the recently published sets of prescribing indicators were developed to be used specifically for mental health disorders and medications, and the PSIs group as a whole did not cover all known types of prescribing problems. The lists of potential PSIs and broader mental health related indicators identified in this review ([S2](#pone.0217406.s002){ref-type="supplementary-material"} and [S3](#pone.0217406.s003){ref-type="supplementary-material"} Files) have been identified from different types of studies with different purposes, settings and populations. In addition, the majority of these studies did not focus on patients with mental illness or clinical practice within specialist MH settings. Therefore, these indicators may not reflect all potential PSIs in metal health context. Hence, we have labelled these indicators as 'potential' and further development and validation may be recommended before they are applied into clinical practice locally. There is therefore a need to develop a new set of prescribing safety indicators specifically for application to patients with mental illness that addresses broad areas of potentially hazardous prescribing and drug monitoring in this population, and to undergo consensus-based refinement and validation with experts in mental health and medication management. As the identified indicator lists contain medications licensed in different countries across the globe, these might therefore be used as a foundation for other international research/clinical groups to achieve this goal by selecting relevant indicators for validation and feasibility processes for their specific countries and health settings, whether in specialist mental health hospitals/institutions or in primary care settings. In addition, because the database search strategy did not include any mental health terms, the list of included studies ([Table 2](#pone.0217406.t002){ref-type="table"}) can be used as a source to identify indicators across a broad range of clinical conditions for populations across primary and secondary care.

In the UK, work is already underway across primary and secondary care to integrate PSIs into everyday clinical practice to identify patients at risk of harm, such as PNCER tool \[[@pone.0217406.ref136]\], investigating medication prescribing accuracy for critical error types (iMPACT) tool \[[@pone.0217406.ref137]\] and Salford medication safety (SMASH) dashboard \[[@pone.0217406.ref138], [@pone.0217406.ref139]\]. This has benefits for patient safety and this study is an important step towards achieving a similar aim for those with mental illness.

Strength and limitations {#sec033}
------------------------

Important strengths of this review include using seven databases for a comprehensive literature search, no limitation on languages to avoid language bias, no restriction on health settings or age group to capture the widest range of prescribing indicators and using a long-time frame of 28 years. In addition, our list of potential indicators was not restricted to practice in a specific country. A number of limitations were identified for this study. Despite efforts to enhance the comprehensiveness of the review by using a rigorous and thorough search strategy, it cannot be confirmed that the review located all relevant studies. The screening process was conducted by one author, which can increase the likelihood of discarding relevant articles \[[@pone.0217406.ref140]\]. No formal quality assessment too has been used to assess the quality of each included study. Not all of the identified MH related indicators were considered to have high clinical importance and may be likely to cause significant risk of harm, and they therefore might not be appropriate to assess the safety of prescribing. Accordingly, we attempted to select indicators, based on the clinical experience of the research team, which could be used to assess the safety of prescribing. Our selection process resulted in 245 indicators that were considered potentially appropriate to assess the safety of prescribing and drug monitoring. However, it is important to recognise inherent limitations in our process of PSI selection. Firstly, the selection of PSIs from published studies was carried out by two pharmacists using their clinical experience, knowledge of PSIs and the published literature. Secondly, some indicators that targeted the elderly or a specific medication were modified to cover all ages or a drug class, respectively if another indicator was present describing this association that the team felt was more appropriate, which we carried out based on the same sources of information. Together, these potential limitations in our selection process mean that we cannot therefore exclude the possibility that we may have overlooked or misinterpreted practice in both ours and other countries, and we therefore recommend that PSI suites using the findings of our review are further developed and validated by panels of health care professionals/experts with experience in the intended country of application in future using consensus building approaches.

Conclusion {#sec034}
==========

This is the first systematic review to identify a list of potential PSIs related to MH disorders and medications that may be used to assess the safety of prescribing. Examination of the included studies and the types of the identified potential PSIs extracted highlights the need for development of a suite of PSIs specific to patients with mental illness, and which covers all known areas of hazardous prescribing and drug monitoring in this patient group. The findings of this review should be used as a foundation for others across the globe to develop, validate and apply their own PSIs for patients with mental illness across different settings to monitor and improve patient care.
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